The biotech deck audit: why deals die on structure, not science
Investors pass less because your biology is weak and more because your story makes risk, and the plan to retire it, hard to see.
Updated May 15, 2026
Great science loses when the narrative makes investors do the work. The remedy isn't more slides; it's better architecture.
The market context that makes this urgent
The funding environment has reset permanently from its 2021 peak. US life sciences venture capital fell from 49.3 billion dollars in 2021 to roughly 26.3 billion dollars in 2024, back near 2018 and 2019 levels, according to Alacrita's analysis of Pitchbook and NVCA data.[1] Venture capital firms invested 25% fewer dollars in biotech companies in 2023 compared to the year prior, according to Pitchbook.[2] VCs now wait for companies to enter or have a clear road map to clinical trials before committing capital, with later-stage drug companies accounting for roughly 40% of all deals in 2023.[2]
The consequence for early-stage founders is not that good science goes unfunded. It is that good science presented without a clear risk retirement narrative goes unfunded. The average investor spends 2 minutes and 24 seconds on a pitch deck in 2024 and 2025, according to Funding Blueprint's analysis of current VC behaviour.[3] In 2023, VCs spent around 20% less time reviewing decks than the year before.[3] In that window, the deck must answer one question before any other: how does each euro in this raise retire a specific risk that stands between this asset and a deal?
A deck that cannot answer that question in the first three slides does not get to slide four.
The cost of a bad deck
Sophisticated investors rarely reject biotech because the idea is incomprehensible. They reject because the deck obscures how value moves. These patterns do most of the damage.
The science wall
Complex figures, unlabelled charts, and no relevance to a clinical or commercial path cause investors to tune out. Fund only the data that proves the case.
Fluffy problem statements
"Cancer is a big problem" is not a position. Define whose pain, what gap, and why now, with the reason it persists despite existing treatments.
Platform optimism
The deck needs a lead asset with a specific indication, a specific endpoint, and a specific acquirer rationale. Platform decks without a beachhead signal that the founders have not yet decided what they are building.
Orphaned preclinical data
Cherry-picked studies, missing controls, or results that do not map to clinical endpoints erode trust. Each figure is a risk claim. It must hold.
Vague roadmaps
No regulatory logic, heroic timelines, and no defined inflection point at which someone's risk model changes. The milestone map is the spine of the investment case. If it is absent, the case has no spine.
Financial disconnection
Activities listed as milestones, use of funds as percentage allocations rather than risk retirement events. Every euro must be traceable to a specific probability shift.
All-scientist team
Investors back people who can execute: clinical operations, regulatory navigation, BD. A team built to invent and not to execute is a red flag, regardless of publication record.
The audit: seven questions that reveal the structure
The following seven questions form a practical self-audit. They mirror the questions a VC associate runs through in the first read of a deck. A founder who cannot answer all seven in one sentence each has structural work to do before the next investor conversation.
What is the single gating uncertainty?
Not a list of risks. The one uncertainty that, unresolved, prevents any deal from proceeding. If the answer requires more than fifteen words, the uncertainty has not been identified.
What milestone retires it?
A named evidence event with a named completion date, stated in terms of what it proves rather than what it does. "Completion of Phase IIa" is an activity. "Proof-of-concept data demonstrating X in the primary indication, moving clinical probability from 25% to 45%" is a milestone.
Who is the named acquirer?
Not a category. A company with a named therapeutic area, a named pipeline gap, and a named reason the asset solves a problem they have right now. If the answer is "a major pharma", the exit has not been defined.
What is the current rNPV and what does the raise move it to?
Two numbers. Current expected value. Post-milestone expected value. The difference is the return being offered. If neither number exists, the ask has not been constructed.
What does the IP actually protect?
Composition of matter, method of use, or formulation? In which markets? Until when? A one-sentence answer that includes expiry date and key jurisdictions. Anything longer signals the IP position has not been stress-tested.
What is the regulatory precedent?
A named comparable approval in the same indication, same modality, or same patient population. If the regulatory pathway is novel, the probability of success cannot be estimated and the rNPV cannot be defended.
What happens if the milestone is negative?
Most decks have no answer. A founder who has thought through the failure scenario (what the data would still prove, what optionality remains, what the next conversation looks like) is a founder investors trust more, not less.
A fundraise deck is an argument under time pressure. Sequence matters because each slide should answer the next question forming in an investor's mind.
Design for a two-minute read
A fundraise deck is an argument under time pressure. Sequence matters because each slide should answer the next question forming in an investor's mind.
The narrative spine
If a slide requires you to be in the room to explain it, it belongs in diligence, not the deck. This is not dumbing down. It is signal design.
The two-minute read test is simple. Remove yourself from the room. Send the deck to someone who does not know the science. Ask them to read it in two minutes and answer: what is the problem, what does the company do, who buys it at exit, and what does the raise fund? If any answer is wrong or missing, the architecture has a gap.
Like what you're reading?
Subscribe for more strategic notes on biotech and venture design.
Anchor the ask to binary gates
Valuation in biotech does not move linearly. Value increases are almost always discrete, tied to clinical read-outs, regulatory decisions, or partnership announcements. Framing the raise as funding eighteen months of activity misses the point. The raise funds three binary gates.
A credible 12-month milestone plan typically features three inflections in biotech: IND filing completed (safety risk down), CMC scale batch released (manufacturing risk down), and pre-IND feedback received (regulatory risk down). Each should have budget contours and a go/no-go decision attached.
Teams built to execute (and the honesty test)
Academic rosters signal risk in capital efficiency, regulatory navigation, and BD. Investors look for people who have done the hard parts before: founders who acknowledge gaps and show how they are being filled, through advisors, fractional executives, or first hires.
Your audit should call out operators on the slide and make their value obvious in one line each.
The deck as a diligence artifact
A good deck reads clean because it is clean: a data room spine, an investor FAQ, a milestone map, an investor budget. That discipline is why sophisticated investors believe you can spend efficiently.
In biotech, clarity is not cosmetic. It is how you convert complex science into priced belief. Design the deck to show risk falling on schedule, and the conversation that follows will be about terms, not trust.
Sources
- 1Alacrita, VC Advisory and Execution Support, analysis of Pitchbook and NVCA biotech venture funding data 2018–2024. alacrita.com/biotech-vc-support ↩
- 2Pitchbook, Q4 2023 Biopharma Report (March 2024), reported via FierceBiotech: VC investment in biopharma fell from $36.7B (2022) to $29.9B (2023), with later-stage deals dominating allocation. fiercebiotech.com ↩
- 3Funding Blueprint, Investor Attention Span: Why VCs Scan Pitch Decks Not Read Them: average investor review time of 2:24 in 2024–2025, down ~20% from prior year. fundingblueprint.io/vc-pitch-deck-review-time ↩
Frequently asked questions
Continue with
Deals die on structure, not science. Before you step into the next boardroom, let's stress-test your narrative and align it with what investors actually need to see.
Audit your pitch deck